Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor (GIPR/GLP-1R) agonist, has, in clinical trials, demonstrated greater reductions in glucose, body weight, and triglyceride levels compared with selective GLP-1R agonists in people with type 2 diabetes (T2D). However, cellular mechanisms by which GIPR agonism may contribute to these improved efficacy outcomes have not been fully defined. Using human adipocyte and mouse models, we investigated how long-acting GIPR agonists regulate fasted and fed adipocyte functions. In functional assays, GIPR agonism enhanced insulin signaling, augmented glucose uptake, and increased the conversion of glucose to glycerol in a cooperative manner with insulin; however, in the absence of insulin, GIPR agonists increased lipolysis. In diet-induced obese mice treated with a long-acting GIPR agonist, circulating triglyceride levels were reduced during oral lipid challenge, and lipoprotein-derived fatty acid uptake into adipose tissue was increased. Our findings support a model for long-acting GIPR agonists to modulate both fasted and fed adipose tissue function differentially by cooperating with insulin to augment glucose and lipid clearance in the fed state while enhancing lipid release when insulin levels are reduced in the fasted state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345
Self-citationAdriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Research works printed but not linked: 23
- Wilson, 2020, The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes, Diabetes Obes. Metab., 22, 2451, 10.1111/dom.14174 · DOI · Paper page
- Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J. Clin. Endocrinol. Metab., 76, 912
- Hansen, 2021, Whole-brain activation signatures of weight-lowering drugs, Mol. Metab., 47, 10.1016/j.molmet.2021.101171 · DOI · Paper page
- Rudovich, 2007, GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women, Regul. Pept., 142, 138, 10.1016/j.regpep.2007.02.006 · DOI
- Campbell, 2022, GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue, Diabetes, 71, 1115, 10.2337/db21-1166 · DOI · Paper page
- Lynggaard, 2020, GIP(3-30)NH2 - a tool for the study of GIP physiology, Curr. Opin. Pharmacol., 55, 31, 10.1016/j.coph.2020.08.011 · DOI
- Deacon, 2000, Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide, J. Clin. Endocrinol. Metab., 85, 3575
- Kuzio, 1974, Radioimmunoassay for gastric inhibitory polypeptide, Gastroenterology, 66, 357, 10.1016/S0016-5085(74)80134-4 · DOI · Paper page
- Eissing, 2013, De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health, Nat. Commun., 4, 1528, 10.1038/ncomms2537 · DOI · Paper page
- Allister, 2015, In vivo 2H2O administration reveals impaired triglyceride storage in adipose tissue of insulin-resistant humans, J. Lipid Res., 56, 435, 10.1194/jlr.M052860 · DOI · Paper page
- Rotondo, 2017, Glycerol is synthesized and secreted by adipocytes to dispose of excess glucose, via glycerogenesis and increased acyl-glycerol turnover, Sci. Rep., 7, 8983, 10.1038/s41598-017-09450-4 · DOI
- Nye, 2008, Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat, J. Biol. Chem., 283, 27565, 10.1074/jbc.M804393200 · DOI · Paper page
- Rasouli, 2007, Ectopic fat accumulation and metabolic syndrome, Diabetes Obes. Metab., 9, 1, 10.1111/j.1463-1326.2006.00590.x · DOI · Paper page
- Tan, 2008, Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese, Biochem. Soc. Trans., 36, 935, 10.1042/BST0360935 · DOI · Paper page
- Merkel, 2002, Lipoprotein lipase: genetics, lipid uptake, and regulation, J. Lipid Res., 43, 1997, 10.1194/jlr.R200015-JLR200 · DOI · Paper page
- Kim, 2010, GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene, J. Lipid Res., 51, 3145, 10.1194/jlr.M006841 · DOI · Paper page
- Christensen, 2015, Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes, Diabetes, 64, 72, 10.2337/db14-0440 · DOI · Paper page
- Frayn, 1998, Non-esterified fatty acid metabolism and postprandial lipaemia, Atherosclerosis, 141, S41, 10.1016/S0021-9150(98)00216-0 · DOI
- Joo, 2017, Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice, Diabetes, 66, 868, 10.2337/db16-0758 · DOI · Paper page
- Carswell, 2012, Culture of isolated human adipocytes and isolated adipose tissue, Methods Mol. Biol., 806, 203, 10.1007/978-1-61779-367-7_14 · DOI
- Basu, 2011, Determination of lipoprotein lipase activity using a novel fluorescent lipase assay, J. Lipid Res., 52, 826, 10.1194/jlr.D010744 · DOI · Paper page
- Bolstad, 2003, A comparison of normalization methods for high density oligonucleotide array data based on bias and variance, Bioinformatics, 19, 185, 10.1093/bioinformatics/19.2.185 · DOI · Paper page
- Rensen, 1997, Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo, J. Lipid Res., 38, 1070, 10.1016/S0022-2275(20)37190-X · DOI · Paper page
Cited by
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00092-0 · Cited by 57
Self-citationNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Metadata
- Authors
- Regmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., Lin, Y., Hu, H., Konkol, D. L., Wojnicki, S., Holland, A. K., Friedrich, J. L., Brown, R. A., Estelle, A. S., Badger, H. S., Gaidosh, G. S., Kooijman, S., Rensen, P. C. N., Coskun, T., Thomas, M. K., & Roell, W.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 36
- Issue
- 7
- Pages
- 1534-1549.e7
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W4399671023
- Cited by
- 130
- References
- 34
- FWCI
- 30.75
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-08-06)
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Leids Universitair Medisch Centrum
- Eli Lilly and Company (CVON 2017-20)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. https://app.cochat.ai/papers/10.1016/j.cmet.2024.05.010
- The paper
- Regmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., Lin, Y., Hu, H., Konkol, D. L., Wojnicki, S., Holland, A. K., Friedrich, J. L., Brown, R. A., Estelle, A. S., Badger, H. S., . . . Roell, W. (2024). Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metabolism. https://doi.org/10.1016/j.cmet.2024.05.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.